Diagnostic performance of expression of PCA3, hepsin and mir biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer

Prostate

Volumn 75, Issue 5, 2015, Pages 539-549

  Roberts, Matthew J ^a,b   Chow, Clement W K ^a   Schirra, Horst Joachim ^a   Richards, Renee ^a   Buck, Marion ^c   Selth, Luke A ^d   Doi, Suhail A R ^a   Samaratunga, Hema ^e   Perry Keene, Joanna ^f   Payton, Diane ^f   Yaxley, John ^b   Lavin, Martin F ^a   Gardiner, Robert A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF FREIBURG   (Germany)

^d University of Adelaide   (Australia)

^e Aquesta Pathology   (Australia)

^f Anatomical Pathology   (Australia)

Author keywords

Ejaculate; Hepsin and PSA; MRNA and microRNA; PCA3; Prostate cancer

Indexed keywords

HEPSIN; MICRORNA; MICRORNA 125B; MICRORNA 200B; MICRORNA 200C; MICRORNA 375; PROSTATE ANTIGEN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; RNA; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; SERINE PROTEINASE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RISK; CLINICAL EVALUATION; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EJACULATION; GENE AMPLIFICATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; BLOOD; METABOLISM; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; SPERM; STATISTICAL MODEL;

AGED; ANTIGENS, NEOPLASM; HUMANS; LOGISTIC MODELS; MALE; MICRORNAS; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; ROC CURVE; SEMEN; SENSITIVITY AND SPECIFICITY; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84923417117     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22942     Document Type: Article

References (39)

1. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0ng/ml or lower. JAMA 2005; 294(1):66-70.
2. Roobol MJ, Schröoder FH, Crawford E.D., Freedland SJ, Sartor AO, Fleshner N. A framework for the identification of men at increased risk for prostate cancer. J Urol 2009; 182(5):2112-2122.
3. Hori S, Blanchet JS, McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: A review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int 2012; DOI: 10.1111/j.1464-410X.;1;2012.11329.x.
4. Kanthabalan A, Emberton M, Ahmed H.U., Biopsy strategies, for selecting, patients for, focal therapy, for prostate, cancer. Curr Opin Urol Epub 2014/03/29. 2014.
5. Samaratunga H, Yaxley J, Kerr K., McClymont K, Duffy D. Significance of minute focus of adenocarcinoma on prostate needle biopsy. Urology 2007; 70(2):299-302.
6. Quann P, Jarrard DF, Huang W. Current prostate biopsy protocols cannot reliably identify patients for focal therapy: Correlation of low+risk prostate cancer on biopsy with radical prostatectomy findings. Int J Clin Exp Pathol 2010; 3 (4):401-407.
7. Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7(2):101-109.
8. Pal RP, Elmussareh M, Chanawani M., Khan MA. The role of a standardized 36 core template-assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography-guided prostate biopsies. BJU Int 2012; 109(3):367-371.
9. Roobol MJ. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urology 2011; 21 (3):225-229.
10. Salami SS, Schmidt F, Laxman B., et al. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol: Seminars and Original Investigations. In Press. doi:10.1016/j.urolonc.2011.04.001.
11. Tomlins SA, Aubin SM, Siddiqui J, Lonigro R.J., et al. Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011; 3:94.
12. Stephan C, Jung K, Semjonow A., et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2] proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013; 59(1):280-288.
13. Tallon L, Luangphakdy D, Ruffion A., et al. Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness. Int J Mol Sci 2014; 15 (8):13299-13316.
14. Thompson J, Lawrentschuk N, Frydenberg M., Thompson L, Stricker P. Usanz. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int 2013; 112:6-20.
15. Bjurlin MA, Taneja SS. Standards for prostate biopsy. Curr Opin Urology 2014; 24 (2):155-161.
16. Gardiner RA, Samaratunga ML, Gwynne R.A., et al. Abnormal prostatic cells in ejaculates from men with prostatic cancer: A preliminary report. Brit J Urol 1996; 78(3):414-418.
17. Landers KA, Burger MJ, Tebay M.A., et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 2005; 114(6):950-956.
18. Landers KA, Samaratunga H, Teng L., et al. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Brit J Cancer 2008; 99(3):491-501.
19. th Annual Scientific Meeting. Thala 2009.
20. Selth LA, Roberts MJ, Chow CWk, et al. Human seminal fluid as a source of prostate cancer specific microRNA biomarkers. Endocr-Relat Cancer 2014; DOI:10.1530/erc-14-0234
21. Yang Q, Zheng Y, Zhu D. Diagnostic performance of micro-RNAs expression in prostate cancer. Tumour Biol 2014; Jul 25.
22. Drabovich AP, Saraon P, Jarvi K., et al. Seminal plasma as a diagnostic fluid for male reproductive system disorders. Nat Rev Urol 2014; 11:278-288.
23. Neuhaus J, Schiffer E. Wilcke P von, Leung H, et al. Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease. PlosOne 2013; 8(6):e67514.
24. Samaratunga H, Montironi R, True L., et al. International society of urological pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. 2011; 24 (1):6-15.
25. D'Amico AV, Whittington R, Malkowicz S., et al. BIochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280(11):969-974.
26. Bangma CH, Bul M, Roobol M. The Prostate cancer research international: Active surveillance study. Curr Opin Urol 2012; 22 (3):216-221.
27. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29(9):e45.
28. Hessels D, Klein GJM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44(1):8-15.
29. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44 (3):837-845.
30. Dimakakos A, Armakolas A, Koutsilieris M. Novel tools for prostate cancer prognosis, diagnosis, and follow-up. Biomed Res Int 2014. doi:10.1155/2014/890697
31. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54(5):1081-1088.
32. Crawford ED, Rove KO, Trabulsi E.J., et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: A prospective study of 1, 962 cases. J Urol 2012; 188(5):1726-1731.
33. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310(5748):644-648.
34. Eguchi FC, Faria EF, Scapulatempo Neto, et al. The role of TMPRSS2:ERG in molecular stratification of PCa and its association with tumor aggressiveness: A study in Brazilian patients. Sci Rep 2014; 10(4):5640.
35. Steurer S, Mayer PS, Adam M, et al. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. Eur Urol 2014; 66(6):978-981.
36. Bradley LA, Palomaki GE, Gutman S, Samson D., Aronson N. Comparative effectiveness review: Prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol 2013; 190(2):389-398.
37. Killick E, Morgan R, Launchbury F., et al. Role of engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Sci Rep 2013; 3:2059.
38. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis N.K., Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: A systematic review and meta-analysis of cohort studies. Cir: Cardiovasc Qual Outcomes 2013; 6(1):99-109.
39. Chew KK, Gibson N, Sanfilippo F., Stuckey B, Bremner A. Cardiovascular mortality in men with erectile dysfunction: Increased risk but not inevitable. J Sexual Med 2011; 8(6):1761-1771.